Simplify Logo

Full-Time

Principal Scientist Vaccine Drug Substance Development Insect Cells & Baculoviruses

Vaccines

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Expert

Toronto, ON, Canada

Hybrid position requiring in-office presence.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or MD/PhD, Engineer with 10+ years of experience developing multi-disciplinary vaccine development programs.
  • Experience in drug substance development and industrialization strongly required.
  • Understanding of complex R&D landscapes globally, ability to identify cutting-edge technologies and new directions, strong academic and biotech/pharma scientific networks.
  • Must have experience and expertise with insect cells/baculoviruses.
  • Experience with mammalian cells (e.g. Vero cells), molecular biology, cell line development would be appreciated.
  • Good oral communication, management, and interpersonal skills.
  • Fluent in English.
Responsibilities
  • Lead implementation of insect cells/baculoviruses “Seeds” and “Upstream” technical activities at Toronto site.
  • Ensure mastery and improvement of the Insect cells (SF)/baculoviruses platform : from seeds/banks to upstream stages including molecular engineering of baculoviruses.
  • Leverage expertise and strong global network to lead definition & realization of CMC platform advancements in particular for the Baculoviruses/Insect cells platform.
  • This role can balance a 'proximity' to lab activities (including doing some lab work) with some strategic elements.
  • Drive innovation within Global Vaccine Drug Substance Development by proposing product, equipment’s and technologies assessment.
  • Contribute to ensure the successful transfer of processes, techniques, information and systems from Global Vaccine Drug Substance Development to VCDS GMP group.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, which help it maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

Grant

Total Funding

$2B

Headquarters

Paris, France

Founded

N/A

Growth & Insights
Headcount

6 month growth

-10%

1 year growth

-10%

2 year growth

-10%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's strong financial performance, as evidenced by its raised 2024 outlook, indicates robust growth and stability.
  • The company's strategic investments in innovative biotech firms, such as Ventyx Biosciences, enhance its pipeline and potential for breakthrough therapies.
  • Sanofi's Dupixent receiving a positive recommendation for expanded use in children demonstrates its leadership in addressing unmet medical needs.

What critics are saying

  • The highly competitive pharmaceutical market requires Sanofi to continuously innovate to maintain its market position.
  • Regulatory challenges in different regions could delay product approvals and impact revenue streams.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts and strategic partnerships, such as with Orano Med for radioligand therapies, set it apart in the competitive pharmaceutical landscape.
  • The company's global reach and focus on patient-centric solutions allow it to effectively navigate diverse regulatory environments and deliver innovative treatments worldwide.
  • Sanofi's investment in sustainable initiatives, like SureChill's 'Cooling as a Service' model, highlights its commitment to addressing healthcare challenges in emerging markets.

Help us improve and share your feedback! Did you find this helpful?